School of Chemical Sciences, The University of Auckland, Auckland 1010, New Zealand.
Maurice Wilkins Centre for Molecular Biodiversity, The University of Auckland, Auckland 1010, New Zealand.
Molecules. 2021 Sep 27;26(19):5847. doi: 10.3390/molecules26195847.
The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has resulted in a significant market 'boom', garnering worldwide attention. Despite ADCs presenting huge challenges to researchers, particularly regarding the identification of a suitable combination of antibody, linker, and payload, as of September 2021, 11 ADCs have been granted FDA approval, with eight of these approved since 2017 alone. Optimism for this therapeutic approach is clear, despite the COVID-19 pandemic, 2020 was a landmark year for deals and partnerships in the ADC arena, suggesting that there remains significant interest from Big Pharma. Herein we review the enthusiasm for ADCs by focusing on the features of those approved by the FDA, and offer some thoughts as to where the field is headed.
大量新兴的癌症治疗抗体药物偶联物（ADC）引发了显著的市场“繁荣”，引起了全球关注。尽管 ADC 给研究人员带来了巨大的挑战，特别是在确定合适的抗体、连接子和有效载荷组合方面，但截至 2021 年 9 月，已有 11 种 ADC 获得了 FDA 的批准，其中 8 种仅在 2017 年之后获得批准。尽管受到 COVID-19 大流行的影响，但这种治疗方法的前景依然乐观，2020 年是 ADC 领域交易和合作的标志性一年，这表明大型制药公司仍然对此领域有浓厚的兴趣。本文通过重点关注 FDA 批准的 ADC 的特点，综述了 ADC 的发展前景，并对该领域的未来发展方向进行了探讨。
